Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...

Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

However, one significant problem has proven surprisingly durable: misdiagnosis of Type 1 diabetes (T1D). Estimates suggest ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

Each Sunday we feature a highlight reel of various articles posted on our website that week.

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...